References
- Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386 (9996):896–912.
- Oertel WH. Recent advances in treating Parkinson’s disease. F1000Res. 2017;6(260).
- Luckey A, Livingston E, Taché Y. Mechanisms and Treatment of Postoperative Ileus. Arch Surg. 2003;138(2):206–14.
- Zheng R, Devin CL, Pucci MJ, et al. Optimal timing and route of nutritional support after esophagectomy: A review of the literature. World J Gastroenterol. 2019;25(31):4427–36.
- Daniel M, Al Dhib R, Mendoza M, et al. Understanding and Managing Metabolic Deficiencies Post Bariatric and Esophagectomy Surgeries: A Narrative Review of the Literature. Cureus. 2024;16(5):e60192.
- Marical A, Medrano IH, Canovas AA, et al. Perioperative Management of Parkinson’s Disease. Cir Esp. 2011;89(7):427–31.
- Wuellner U, Kassubek J, Odin P, et al. Transdermal rotigotine for the perioperative management of Parkinson’s disease. J Neural Transm. 2010;117:855–9.
- Broussolle E, Marion MH, Pollak P. Continuous subcutaneous apomorphine as replacement for levodopa in severe parkinsonian patients after surgery. Lancet. 1992; 340(8823):859–60.
- Gálvez-Jiménez N, Lang AE. Perioperative problems in Parkinson’s disease and their management: apomorphine with rectal domperidone. Can J Neurol Sci. 1996;23(3):198–203.
- Kim YE, Kim HJ, Yun JY, Jeon BS. Intravenous amantadine is safe and effective for the perioperative management of patients with Parkinson’s disease. J Neurol. 2011;258(12):2274–5.
- Olanow CW, Espay AJ, Stocchi F, et al. Continuous Sub- cutaneous Levodopa Delivery for Parkinson’s Disease: A Randomized Study. J Parkinsons Dis. J Parkinsons Dis. 2021;11(1):177–86.
- Doggrell SA. Continuous subcutaneous levodopa-carbidopa for the treatment of advanced Parkinson’s disease: is it an improvement on other delivery? Expert Opin Drug Deliv. 2023;20(9):1189–99.
- Siddiqi SH, Abraham NK, Geiger CL, et al. The Human Experience with Intravenous Levodopa. Front Pharmacol. 2016;6:307.
- Brennan KA, Genever RW. Managing Parkinson’s disease during surgery. BMJ. 2010;341:c5718.
- Raz A, Lev N, Orbach-Zinger S, Djaldetti R. Safety of perioperative treatment with intravenous amantadine in patients with Parkinson disease. Clin Neuropharmacol. 2013;36(5):166–9.
- Rektor I, Babic T, Boothmann B, et al. High doses of rotigotine transdermal patch: results of an open-label, dose-escalation trial in patients with advanced-stage, idiopathic Parkinson disease. Clin Neuropharmacol. 2009;32(4):193–8.
- Goetz CG, Blasucci L, Stebbins GT. Switching Dopamine Agonists in Advanced Parkinson’s Disease: Is Rapid Titration Preferable to Slow? Neurology. 1999;52(6):1227–9.
- Chung SJ, Asgharnejad M, Bauer L, et al. Switching From an Oral Dopamine Receptor Agonist to Rotigotine Transdermal Patch: A Review of Clinical Data With a Focus on Patient Perspective. Expert Rev Neurother. 2017;17(7):737–49.